Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Jan 17:15:1501813.
doi: 10.3389/fimmu.2024.1501813. eCollection 2024.

Severe metabolic accumulation of VV116 in kidney transplant patients with impaired renal function: a case series report

Jiaying Zhang #  1 , Yuan Gao #  2 , Xiaoyun Miao #  3 , Wei Wang  4 , Zhongkai Zhou  4 , Yunyi Gao  5 , Liwei Liu  2 , Menghua Wu  6 , Ke Ma  7 , Ling Zhou  7 , Yan Yang  7 , Sha Meng  8 , Yingmei Feng  8 , Zhuorui Zhao  9 , Wei Liu  10 , Danlei Mou  1 , Zixin Kang  1 , Lianchun Liang  1 , Zhongjie Hu  11
Affiliations
Case Reports

Severe metabolic accumulation of VV116 in kidney transplant patients with impaired renal function: a case series report

Jiaying Zhang et al. Front Immunol. .

Abstract

The treatment of COVID-19 in the post-transplant individuals is challenging, primarily due to the drug-drug interaction between nirmatrelvir/ritonavir and tacrolimus. Deuremidevir hydrobromide tablets (VV116) is an orally small molecule agents target SARS-CoV-2 RdRp and inhibits viral replication. It may have a low likelihood of drug-drug interactions and has a potential to provide new treatment option. We described three cases of renal transplant patients with concomitant impaired renal function who developed COVID-19 pneumonia and were treated with VV116. Despite varying degrees of drug accumulation, these patients achieved rapid viral clearance and showed prompt improvement in pneumonia symptoms. Notably, tacrolimus blood concentrations remained within the therapeutic range throughout treatment, and no clinically significant adverse events were observed despite the drug accumulation.

Keywords: COVID-19; VV116; drug accumulation; kidney dysfunction; organ transplant.

PubMed Disclaimer

Conflict of interest statement

YG declares receiving consulting fees from Sinovac and lecture fees from Pfizer over the past 36 months. Authors KM, LZ, and YY were employed by United-Power Pharma Tech Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
(A). VV116-N1 concentration, virologic results and medicine administration for case 1, Serial chest imaging by computed tomography (CT), the image on June 7th was from another hospital and taken with a mobile phone camera. (B). VV116-N1 concentration, virologic results and medicine administration for case 2, the Ct. value of N-gene on February 26th was from another hospital, Serial chest imaging by computed tomography (CT), the image was taken on February 27th, March 1st and March 7th. (C). VV116-N1 concentration, virologic results and medicine administration for case 3, the Ct. value of N-gene on April 8th was from another hospital, Serial chest imaging by computed tomography (CT), the image was taken on April 10 th and April 13 th.
See this image and copyright information in PMC

References

    1. Fishbane S, Hirsch JS, Nair V. Special considerations for paxlovid treatment among transplant recipients with Sars-Cov-2 infection. Am J Kidney Dis. (2022) 79:480–2. doi: 10.1053/j.ajkd.2022.01.001 - DOI - PMC - PubMed
    1. Jiang M, Gao Y, Hu Z. Pharmacological innovation and clinical value of vv116. Lancet Infect Dis. (2024) 24:e212. doi: 10.1016/S1473-3099(24)00009-4 - DOI - PubMed
    1. Villar PME, Mendes PRA, Kiyota TA, Engleitner HA, Tamesawa CS, Morello MM, et al. Oximetry at Admission as a Predictor of Tomographic and Functional Impairment after 3-6 Months in Hospitalized Patients with Covid-19. J Int Med Res. (2023) 51:3000605231177187. doi: 10.1177/03000605231177187 - DOI - PMC - PubMed
    1. Zhu Y, Chen D, Zhu Y, Ge X, Li Z, Miao H. Clinical observation of glucocorticoid therapy for critically ill patients with Covid-19 pneumonia. J Int Med Res. (2023) 51:3000605221149292. doi: 10.1177/03000605221149292 - DOI - PMC - PubMed
    1. Liu W, Zhang M, Hu C, Song H, Mei Y, Liu Y, et al. Remdesivir derivative vv116 is a potential broad-spectrum inhibitor of both human and animal coronaviruses. Viruses. (2023) 15:2295. doi: 10.3390/v15122295 - DOI - PMC - PubMed

Publication types